6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Treatment-seeking patterns for malaria in pharmacies in five sub-Saharan African countries

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Artemisinin-based combination therapy (ACT) is recommended as the first-line anti-malarial treatment strategy in sub-Saharan African countries. WHO policy recommends parasitological confirmation by microscopy or rapid diagnostic test (RDT) in all cases of suspected malaria prior to treatment. Gaps remain in understanding the factors that influence patient treatment-seeking behaviour and anti-malarial drug purchase decisions in the private sector. The objective of this study was to identify patient treatment-seeking behaviour in Ghana, Kenya, Nigeria, Tanzania, and Uganda.

          Methods

          Face-to-face patient interviews were conducted at a total of 208 randomly selected retail outlets in five countries. At each outlet, exit interviews were conducted with five patients who indicated they had come seeking anti-malarial treatment. The questionnaire was anonymous and standardized in the five countries and collected data on different factors, including socio-demographic characteristics, history of illness, diagnostic practices (i.e. microscopy or RDT), prescription practices and treatment purchase. The price paid for the treatment was also collected from the outlet vendor.

          Results

          A total of 994 patients were included from the five countries. Location of malaria diagnosis was significantly different in the five countries. A total of 484 blood diagnostic tests were performed, (72.3% with microscopy and 27.7% with RDT). ACTs were purchased by 72.5% of patients who had undergone blood testing and 86.5% of patients without a blood test, regardless of whether the test result was positive or negative (p < 10 −4). A total of 531 patients (53.4%) had an anti-malarial drug prescription, of which 82.9% were prescriptions for an ACT. There were significant differences in prescriptions by country. A total of 923 patients (92.9%) purchased anti-malarial drugs in an outlet, including 79.1% of patients purchasing an ACT drug: 98.0% in Ghana, 90.5% in Kenya, 80.4% in Nigeria, 69.2% in Tanzania, and 57.7% in Uganda (p < 10 −4). Having a drug prescription was not a significant predictive factor associated with an ACT drug purchase (except in Kenya). The number of ACT drugs purchased with a prescription was greater than the number purchased without a prescription in Kenya, Nigeria and Tanzania.

          Conclusions

          This study highlights differences in drug prescription and purchase patterns in five sub-Saharan African countries. The private sector is playing an increasingly important role in fever case management in sub-Saharan Africa. Understanding the characteristics of private retail outlets and the role they play in providing anti-malaria drugs may support the design of effective malaria interventions.

          Related collections

          Most cited references30

          • Record: found
          • Abstract: found
          • Article: not found

          Artesunate combinations for treatment of malaria: meta-analysis.

          Addition of artemisinin derivatives to existing drug regimens for malaria could reduce treatment failure and transmission potential. We assessed the evidence for this hypothesis from randomised controlled trials. We undertook a meta-analysis of individual patients' data from 16 randomised trials (n=5948) that studied the effects of the addition of artesunate to standard treatment of Plasmodium falciparum malaria. We estimated odds ratios (OR) of parasitological failure at days 14 and 28 (artesunate combination compared with standard treatment) and calculated combined summary ORs across trials using standard methods. For all trials combined, parasitological failure was lower with 3 days of artesunate at day 14 (OR 0.20, 95% CI 0.17-0.25, n=4504) and at day 28 (excluding new infections, 0.23, 0.19-0.28, n=2908; including re-infections, 0.30, 0.26-0.35, n=4332). Parasite clearance was significantly faster (rate ratio 1.98, 95% CI 1.85-2.12, n=3517) with artesunate. In participants with no gametocytes at baseline, artesunate reduced gametocyte count on day 7 (OR 0.11, 95% CI 0.09-0.15, n=2734), with larger effects at days 14 and 28. Adding artesunate for 1 day (six trials) was associated with fewer failures by day 14 (0.61, 0.48-0.77, n=1980) and day 28 (adjusted to exclude new infections 0.68, 0.53-0.89, n=1205; unadjusted including reinfections 0.77, 0.63-0.95, n=1958). In these trials, gametocytes were reduced by day 7 (in participants with no gametocytes at baseline 0.11, 0.09-0.15, n=2734). The occurrence of serious adverse events did not differ significantly between artesunate and placebo. The addition of 3 days of artesunate to standard antimalarial treatments substantially reduce treatment failure, recrudescence, and gametocyte carriage.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Influence of Rapid Malaria Diagnostic Tests on Treatment and Health Outcome in Fever Patients, Zanzibar—A Crossover Validation Study

            Introduction Morbidity and mortality due to Plasmodium falciparum malaria have been increasing in sub-Saharan Africa since the early 1990s, concomitantly with spread of resistance to commonly used monotherapies, i.e., chloroquine and sulfadoxine-pyrimethamine [1], [2]. This increased resistance has necessitated that many African countries change their treatment policy to artemisinin-based combination therapy (ACT) as a first-line treatment for uncomplicated malaria. The restricted use of ACT to confirmed malaria patients is critical. Overuse of the more expensive ACTs will not only put an extra heavy financial burden on malaria control programmes in Africa, but also enhance drug resistance and prevent other causes of fever from being appropriately treated, for example, pneumonias, which require antibiotics. Symptom-based or clinical malaria diagnosis has proven to be quite unspecific [3]–[7]. Malaria diagnosis based on parasitological confirmation is therefore increasingly advocated. Integrated Management of Childhood Illness (IMCI) algorithms based on clinical symptoms could potentially be made more efficient and cost-effective if simple parasitological diagnostic methodologies were incorporated. The use of microscopy has been tried in various health care settings, but is associated with problems of logistics, sustainability, and quality control [8], [9]. The development of rapid diagnostic tests (RDTs) for P. falciparum malaria offers a potential alternative in remote and poorly resourced health facilities that are beyond the reach of high-quality microscopy services [10]–[14]. The combination of RDT and ACT provides an important strategic opportunity to reduce malaria-associated mortality in Africa, and RDT use will potentially improve treatment of other causes of fever, for example, life-threatening bacterial diseases [15], [16]. However, the evidence base is still inadequate for malaria control programmes to recommend the use of RDTs on a large scale. There are several studies on sensitivities and specificities of various malaria diagnostic methods [11]–[14], [16]–[19]. In two recently published studies on the implication of RDT use at the health facility level on drug prescription, both describe major problems with test efficiency when used in clinical practice [15], [20]. However, this may be attributed to different messages regarding the risk of withholding malaria treatment to patients with negative test results [21]. Also, these studies did not describe staff training on technique and validation of RDTs, a prerequisite for the malaria diagnostic tests to become cost effective [22]. Furthermore, and importantly, there are no randomized control trials on the health impact and cost-effectiveness of confirmatory malaria diagnosis based on RDTs [18]. Zanzibar was among the first regions in sub-Saharan Africa to introduce ACT, free of charge through public health care, as both as first- and second- line treatment for uncomplicated malaria, which are provided free of charge through public health care. In view of the fact that many patients with fever are prescribed ACT without being malaria infected, the present study was undertaken to assess, on a wide scale, the added value of RDT to clinical diagnosis (CD) alone for management of patients of all ages presenting with fever at primary health care facilities. The hypothesis was that RDT-aided diagnosis of fever patients would improve rational use of ACTs and possibly other necessary treatments, such as antibiotics to non-malaria patients, with an overall improved health impact. Material and Methods Study Area and Study Health Centres The trial was conducted in four Primary Health Care Units (PHCUs) in Zanzibar, namely, Muyuni and Uzini on Unguja Island, and Kinyasini and Mzambarauni on Pemba Island. The selection of the four study sites aimed to provide a representative picture of Zanzibar with regard to malaria epidemiology as well as previous use of RDT in Zanzibar. By the time of the trial, malaria transmission in Zanzibar was generally considered endemic [23], with recorded malaria parasite rates between 10% and 50% in different age groups (unpublished data, Zanzibar Ministry of Health). A previous clinical trial conducted in two comparable PHCUs had shown an overall malaria parasite prevalence of about 30% among febrile children aged 15 y Total CD+RDT 228/544 (42%) 93/210 (44%) 40/251 (16%) 361/1,005 (36%) CD alone 423/503 (84%) 169/196 (86%) 160/183 (87%) 752/882 (85%) Microscopy 374/1,047 (36%) 128/406 (32%) 50/434 (12%) 552/1,887 (29%) A majority of antimalarial prescriptions were for children below 5 y, 228/361 (63%) in CD+RDT group and 423/752 (56%) in CD alone group. Prescription in relation to microscopy results are presented in Table 2. 10.1371/journal.pmed.1000070.t002 Table 2 Proportions of patients receiving antimalarial drugs and antibiotics in relation to day 0 microscopy results. Drugs Received by Patients Diagnostic Testing Blood Slide Result 15 years Total Antimalarials CD+RDT BS positive 186/200 (93%) 71/72 (99%) 22/33 (67%) 279/305 (91%) BS negative 42/344 (12%) 22/138 (16%) 18/218 (8%) 82/700 (12%) CD alone BS positive 174/174 (100%) 54/56 (96%) 17/17 (100%) 245/247 (99%) BS negative 249/329 (76%) 115/140 (82%) 143/166 (86%) 507/635 (80%) Antibiotics CD+RDT BS positive 51/200 (26%) 4/72 (6%) 3/33 (9%) 58/305 (19%) BS negative 190/344 (55%) 52/138 (38%) 72/218 (33%) 314/700 (45%) CD alone BS positive 38/174 (22%) 4/56 (7%) 1/17 (6%) 43/247 (17%) BS negative 140/329 (43%) 28/140 (20%) 24/166 (14%) 192/635 (30%) A total of 607/1,887 (32%) patients were prescribed antibiotics, including mainly cotrimoxazole, but also ampicillin, amoxicillin, and erythromycin. Prescription of antibiotics was significantly higher in the CD+RDT than CD-alone group, 372/1,005 (37%) and 235/882 (27%) (OR 1.8, 95%CI 1.5–2.2, p 99% for detecting a parasite density of ≥1,000 parasites/µl, 76% and 59% for parasite densities 100–999 and 99% Specificity 88% 20% Positive predictive value 77% 33% Negative predictive value 96% 98% Antimalarial and antibiotic prescriptions in relation to age and BS results are presented in Table 2. Among a total of 552 BS-positive patients, 28 (14 children below age 5 y) were not prescribed antimalarial treatment, 26 after CD+RDT (RDT negative), and two after CD alone. Their parasite densities at enrolment were, however, relatively low (GM 174 parasites/µl blood, range 32–2029). Among patients with BS negative results a total of 82/700 (12%) were prescribed antimalarial drugs in the CD+RDT group (RDT positive) compared with 507/635 (80%) in the CD-alone group (Table 2). A total of 82/361 (23%) antimalarial treatments in the CD+RDT group and 507/635 (80%) in the CD-alone group may thus have been unnecessary according to microscopy results (Tables 1 and 2). In contrast, BS-negative patients received significantly more antibiotics in the CD+RDT group, 314/700 (45%) patients compared with 192/635 (30%) in the CD alone group (OR 2.1, 95%CI 1.6–2.6, p 15 y All ages CD+RDT group General costs 1.90 1.90 1.90 1.90 Drugs 0.39 0.63 0.69 0.51 Reattendance 0.08 0.06 0.03 0.06 Total mean costs 2.37 2.59 2.62 2.47 CD alone group General costs 1.40 1.40 1.40 1.40 Drugs 0.58 0.89 1.55 0.85 Reattendance 0.17 0.05 0.05 0.12 Total mean costs 2.15 2.34 3.00 2.37 All estimates are based on an exchange rate of USD 1 = TSh 1,100. General costs = transport (USD 0.90)+consultation (USD 0.50)+RDT (USD 0.50) = USD 1.90. Drugs = ACT (USD 0.50−1.40)+antibiotics USD (0.30−0.90)+antipyretics (USD 0.05−0.20). Reattendance costs = transport (USD 0.90)+consultation (USD 0.50)+drugs (ACT, antibiotic+antipyretics = average USD 1.10) = USD 2.50. Discussion We found an overall 2-fold reduction in prescription of antimalarial drugs and reattendance of patients due to illness during the two-week follow-up period in the CD+RDT group compared with CD-alone group. Overall costs were, however, similar in the two groups despite a significant reduction of cost among the adult patients after RDT-aided diagnosis. Almost all enrolled fever patients in the CD-alone arm were considered and treated as malaria patients, resulting in high diagnostic sensitivity (99%) but low specificity (20%). This result follows the suggestion that fever alone may be a better criterion for malaria treatment than more complicated algorithms [4]. Studies on clinical diagnostic algorithms have shown that with weighting and scoring systems for clinical signs and symptoms may result in sensitivities of 70%–88% and specificities of 63%–82% [3], [4], [17], [27]. However, these methods may be too complicated to be effective under operational conditions, and the algorithms may be site- and context-specific [4]. Health workers learnt to use RDTs correctly with relative ease, confirming that the tests are simple to perform and interpret [11]. The estimated sensitivity (>100 parasites/µl of blood) is in line with WHO recommendations [10] and is also in accordance with a recent review concluding that the accuracies of the HRP2-based test in P. falciparum–endemic areas are normally high with a mean sensitivity of 93% [13]. The specificity in our study—88%—was similar to or lower than in some previous studies [12], [13], [15], [16], [19]. Especially under field conditions, heat and time stability could be an important impediment for the optimal use of RDTs for malaria, but according to the manufacturer Parachek Pf is expected to be stable at temperatures up to 40°C for up to two years. The use of confirmatory malaria diagnosis with RDT is expected to reduce the overuse of antimalarial drugs by ensuring that treatment is targeted to patients suffering from malaria infections as opposed to treating all patients with fever. Our findings confirm this expectation, although the impact of RDT-aided diagnosis will obviously be highly dependent on the malaria incidence (prevalence of malaria in fever patients) in a given situation. Importantly, in our study, the study nurses showed great confidence in the RDT results as a guide to choice of treatment, as did the patients. This is in contrast to the assumption that care providers, although willing to perform diagnostic tests, do not always comply with the results, especially when the result is negative [15], [20]. High adherence by prescribers in relation to RDT results was, however, also reported in a recent study conducted in mainland Tanzania [28]. We believe that the high compliance and confidence in the RDT in our study may result from a successful pre-study training, although local beliefs, behaviours, and treatment traditions may also account for discrepancies between our results and those of previous publications [15], [20]. We further realise that the study situation, supervision, and incentives provided to the nurses may also affect compliance, but we do not believe it has seriously biased our results. The incentive to the nurses was consistent with common practice for project participation in Zanzibar, but whereas it represented up to approximately a 65% increment of the ordinary salary it was not influenced or affected by performance. Our results obviously need to be confirmed before RDT can be more generally recommended, but we do believe they suggest that RDT use may be efficient if local diagnostic and treatment traditions are properly addressed. Fearing false negative test results and being aware that delays in providing effective treatment can be fatal for malaria patients is reported to be the main reason to prescribe antimalarial drugs despite a negative RDT result. Importantly, in our study, the patients with malaria detected by BS but non-detectable by RDT and therefore not treated with antimalarial drugs had relatively low parasite densities and no patients developed any severe malaria manifestations during the two week follow-up. This supports a general recommendation of consistence in not treating RDT negative patients. Re-testing will, however, obviously be required if the illness remains or aggravates. Our finding of a reduction in perceived illness during a two-week follow-up in the CD+RDT group of patients is critical. This was probably attributed to improved treatment of patients with fever not associated with malaria. More antibiotics were prescribed to the RDT-negative patients. The introduction of RDT and ACT thus provides an opportunity to improve the treatment of both malaria and bacterial diseases. We did consider the potential selection bias of the four health facilities; indeed, significant heterogeneity was observed with regard to the primary effect parameter. We do, however, assume this heterogeneity was at least partly accounted for by multilevel analysis and, since the RDT effect on drug prescriptions was quite large in each PHCU, it seems unlikely to be due to selection bias. The selection of the four study sites was done to provide a relatively representative picture of both malaria epidemiology and previous use of RDT in Zanzibar. Since RDTs had already been introduced by MSF in some parts of Zanzibar we opted for including PHCUs both with previous experience (two sites) and without previous RDT use (two sites). Beside the previous RDT exposure, the selection of the four study sites was based on representing a common rural situation and representing both of the two major islands in Zanzibar, i.e. Unguja and Pemba (two PHCUs on each island). However, we do of course acknowledge that the choice of the four sites remains arbitrary and of low number and thus cannot be fully representative of an overall Zanzibar situation and even less so of an overall situation in sub-Saharan Africa, which indeed is very diverse itself with regard to epidemiology of malaria, cultural and behavioural aspects, health care structure, etc. With the understanding that four PHCUs is a very low number, we used a cross-over design of RDT versus non-RDT weeks within sites. The choice of RDT or non-RDT the first week was based on an allocation with one previous MSF/RDT site being in either arm and one non previous MSF/RDT similarly being in either arm. Still, we acknowledge that there may still be confounding effects with regard to health-seeking behaviour or even selection bias by study nurses on respective weeks by (a) patients/caretakers postponing health care attendance to a week with RDT or staff applying exclusion criteria on a CD week and instead request the patient to return on a RDT week, and/or (b) attending alternate PHCUs where RDT is performed. However, we assume that (a) is less realistic, considering that uncomplicated malaria requires urgent treatment and patients or their caretakers as well as health care workers are therefore not likely to wait and postpone treatment. We also do not believe (b) is realistic because systematic RDT use was not implemented outside study PHCUs at the time of the trial and the study sites were located far from each other. And indeed statistical analysis showed no significant difference between frequencies of fever patient attendance on RDT and non-RDT weeks. The only trend observed with regard to frequency of attendance was a tendency to a relative increase toward the later period of the study, compatible with increased malaria transmission. In summary, RDTs were well performed in peripheral health facilities with acceptable sensitivity and specificity for identifying malaria-attributable fever episodes. The RDT results were adhered to and did provide consistent and significant reduction in antimalarial treatment in parallel with an increase in prescribed antibiotics. This probably contributed to the significant reduction in reattendance due to illness during the two-week follow-up. Our results indicate that RDTs may represent an important tool for improved management of fever patients in peripheral health care settings in malaria-endemic areas, especially where ACT has been introduced for treatment of uncomplicated malaria. Supporting Information Text S1 Trial protocol. (0.15 MB DOC) Click here for additional data file. Text S2 CONSORT checklist. (0.06 MB DOC) Click here for additional data file.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Reduction of anti-malarial consumption after rapid diagnostic tests implementation in Dar es Salaam: a before-after and cluster randomized controlled study

              Background Presumptive treatment of all febrile patients with anti-malarials leads to massive over-treatment. The aim was to assess the effect of implementing malaria rapid diagnostic tests (mRDTs) on prescription of anti-malarials in urban Tanzania. Methods The design was a prospective collection of routine statistics from ledger books and cross-sectional surveys before and after intervention in randomly selected health facilities (HF) in Dar es Salaam, Tanzania. The participants were all clinicians and their patients in the above health facilities. The intervention consisted of training and introduction of mRDTs in all three hospitals and in six HF. Three HF without mRDTs were selected as matched controls. The use of routine mRDT and treatment upon result was advised for all patients complaining of fever, including children under five years of age. The main outcome measures were: (1) anti-malarial consumption recorded from routine statistics in ledger books of all HF before and after intervention; (2) anti-malarial prescription recorded during observed consultations in cross-sectional surveys conducted in all HF before and 18 months after mRDT implementation. Results Based on routine statistics, the amount of artemether-lumefantrine blisters used post-intervention was reduced by 68% (95%CI 57-80) in intervention and 32% (9-54) in control HF. For quinine vials, the reduction was 63% (54-72) in intervention and an increase of 2.49 times (1.62-3.35) in control HF. Before-and-after cross-sectional surveys showed a similar decrease from 75% to 20% in the proportion of patients receiving anti-malarial treatment (Risk ratio 0.23, 95%CI 0.20-0.26). The cluster randomized analysis showed a considerable difference of anti-malarial prescription between intervention HF (22%) and control HF (60%) (Risk ratio 0.30, 95%CI 0.14-0.70). Adherence to test result was excellent since only 7% of negative patients received an anti-malarial. However, antibiotic prescription increased from 49% before to 72% after intervention (Risk ratio 1.47, 95%CI 1.37-1.59). Conclusions Programmatic implementation of mRDTs in a moderately endemic area reduced drastically over-treatment with anti-malarials. Properly trained clinicians with adequate support complied with the recommendation of not treating patients with negative results. Implementation of mRDT should be integrated hand-in-hand with training on the management of other causes of fever to prevent irrational use of antibiotics.
                Bookmark

                Author and article information

                Contributors
                +33 (0) 2 32 88 82 50 , joel.ladner@chu-rouen.fr , joel.ladner@univ-rouen.fr
                ben.davis@axiosint.com
                etienne.audureau@gmail.com
                joseph.saba@axiosint.com
                Journal
                Malar J
                Malar. J
                Malaria Journal
                BioMed Central (London )
                1475-2875
                29 August 2017
                29 August 2017
                2017
                : 16
                : 353
                Affiliations
                [1 ]ISNI 0000 0001 2296 5231, GRID grid.417615.0, Rouen University Hospital, Epidemiology and Health Promotion Department, , Hôpital Charles Nicolle, ; 1 Rue de Germont, 76 031 Rouen Cedex, France
                [2 ]Axios International, Paris, France
                [3 ]ISNI 0000 0001 2292 1474, GRID grid.412116.1, , Paris Est University Hôpital, Henri Mondor Hospital, Public Health, Assistance Publique Hôpitaux de Paris, ; Créteil, France
                Article
                1997
                10.1186/s12936-017-1997-3
                5574241
                28049519
                34c9881d-2516-4b17-864b-336973d6a1b3
                © The Author(s) 2017

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 15 February 2017
                : 18 August 2017
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/100008792, Novartis Pharma;
                Categories
                Research
                Custom metadata
                © The Author(s) 2017

                Infectious disease & Microbiology
                malaria,treatment,act drugs,private sector
                Infectious disease & Microbiology
                malaria, treatment, act drugs, private sector

                Comments

                Comment on this article